Myfembree denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for myfembree are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Myfembree as "Experimental" — and Why This Is Directly Challengeable

Myfembree (relugolix, estradiol, and norethindrone acetate) received FDA approval and is listed in the FDA's approved drug database. An "experimental" or "investigational" denial for an FDA-approved medication is one of the most clearly appealable denial types. Cigna's medical policies define experimental treatments as those lacking sufficient clinical evidence for widespread acceptance — a standard that FDA approval is generally understood to satisfy for the approved indication. If Myfembree is being prescribed within its FDA-approved indication for your condition, this denial has a strong factual basis for reversal.

## The Federal Appeal Framework

• Internal appeal (Level 1): File a written appeal within Cigna's deadline (typically 180 days from the denial). Cigna must respond within 30 days for pre-service non-urgent appeals, or 72 hours for expedited urgent requests.
• External review (ACA §2719): This category of denial — experimental/investigational — is specifically subject to independent external review under the ACA. After exhausting internal appeals, you may request IRO review generally within 4 months of the final adverse determination. External review of experimental denials often favors patients when the drug is FDA-approved for the prescribed indication.
• ERISA §503: For employer-sponsored plans, Cigna must provide a full clinical rationale explaining why an FDA-approved drug is nonetheless considered experimental under their policy.

## Documents to Gather

1. FDA approval confirmation: Print the current FDA label and drug approval page for Myfembree (available at FDA.gov). Highlight the specific approved indication matching your diagnosis. 2. Prescriber letter: A letter from your physician stating the prescribed indication, confirming it falls within the FDA-approved labeling, and citing relevant specialty society guidelines (e.g., from the applicable gynecologic or endocrine specialty organization) that recognize this therapy as a standard treatment option. 3. Diagnosis documentation: Chart records confirming your diagnosis — endometriosis-associated pain or fibroid-related heavy menstrual bleeding — and its clinical severity. 4. Prior treatment history: Documentation of other treatments tried and their outcomes, demonstrating that this is not a first-line experimental attempt but a clinically considered choice. 5. Cigna's experimental/investigational policy: Obtain the specific policy language defining experimental treatment and identify exactly where their analysis of Myfembree falls short — particularly if they failed to account for FDA approval status.

## Criteria-Mapping Structure

Your appeal letter should present a clear, sequential rebuttal:

1. State the FDA-approved indication for Myfembree and the matching diagnosis. 2. Cite Cigna's own definition of "experimental" and demonstrate that FDA-approved drugs used within their approved indication do not meet that definition. 3. Reference the applicable specialty guideline organization that recognizes this therapy — without citing specific statistics. 4. Request that Cigna identify specifically what evidence standard Myfembree fails to meet, and assert that if FDA approval is insufficient, Cigna must explain why in writing.

Experimental denials for FDA-approved medications are among the most frequently overturned on external review.